Open Book Extracts (OBX), a cGMP-certified manufacturer and distributor of cannabinoid ingredients, announced the completion of its first randomized, controlled trial on rare cannabinoids to evaluate the effect they have on longer-term pain, well-being, and quality of life. The study is being conducted with the support of Radicle Science, a health technology B-corp focused on validating health and wellness products for the first time.
 
Radicle conducted a study on several OBX formulations, which ran for four weeks and was of a blinded, randomized, placebo-controlled, parallel group.
 
“We are excited to have partnered with OBX to conduct history’s largest randomized, controlled trial of cannabinoids for pain, involving nearly 2,000 participants from across the U.S. This groundbreaking study also represents history’s first randomized controlled trial on the synergistic impact of rare cannabinoids like CBC and CBG on pain,” said Dr. Jeff Chen, MD, MBA, co-founder and CEO of Radicle Science, said. “A majority of all phytocannabinoid clinical research has centered around THC, and we are uncovering the untapped potential in the other phytocannabinoids found in the cannabis and hemp plant.”
 
The results of the study will be announced upon their return, which is expected by late April of this year.
 
This is only the first of a series of studies on rare cannabinoids undertaken through this partnership. The two companies will launch the first large-scale, blinded, randomized, placebo-controlled clinical trails on rare cannabinoids including THCV, CBN, CBG, and CBC, to study their effects on energy, focus, appetite, sleep disturbance, stress, and anxiety across more than 10,000 study participants.
 
“Validating the therapeutic benefits of cannabinoids with scientifically-backed research is a source of great pride for our company,” Dave Neundorfer, CEO of OBX, said. “We are on a quest to understand the true potential of cannabinoids and thank the Radicle Science team for providing a platform that supports the research that will help transform the CBD industry. The completion of this study is a key milestone in our research efforts and further demonstrates our commitment to scientific research and development for the cannabinoid industry as a whole.”